You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

  • Technology appraisal guidance
  • Reference number: TA171
  • Published:  18 June 2009
  • Last updated:  26 June 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Research recommendations
  2. Guidance into practice

Tools and resources

Tools to help you put the guidance into practice.

Research recommendations

  • Research recommendations information

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top